Risk adjusted net present value: What is the current valuation of AbbVie’s ABBV-400?

ABBV-400 is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase II program in Metastatic Colorectal Cancer.

Study links gut microbiome modulation to changes in social behavior

Taking pro- and prebiotics could make people more sensitive to fairness, even at the cost of earning less money, according to a study.

May 15, 2024

FDA won’t take action against GLP-1 compounders as it rethinks tirzepatide shortage

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 19, 2024

Awakn Life Sciences Announces Conditional Approval of CSE Listing | Psychedelic Invest

Toronto, Ontario–(Newsfile Corp. – February 5, 2024) – Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing medication-assisted

February 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.